Experimental mRNA Vaccine Shows Promise in Early Cancer Trials

Initial results from a Phase 1 trial indicate the vaccine can stimulate the immune system to combat advanced solid tumors without serious side effects.

• The mRNA-4359 vaccine, developed by Moderna, targets advanced melanoma, lung cancer, and other solid tumors.
• In the trial, 19 patients received between one and nine doses, with 8 out of 16 evaluated patients showing no tumor growth or new tumors.
• The vaccine uses mRNA technology to teach the immune system to recognize and attack cancer cells.
• Researchers reported the treatment was well tolerated, with minor side effects such as fatigue and injection site pain.
• The trial is ongoing, enrolling more patients with melanoma and lung cancer to further assess safety and efficacy.

3 Articles

Evening Standard The Independent The Independent